{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:03:11Z","timestamp":1774893791421,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T00:00:00Z","timestamp":1544918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T00:00:00Z","timestamp":1544918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea"},{"name":"The Princess Margaret Cancer Foundation, Toronto, Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41375-018-0321-8","type":"journal-article","created":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T17:15:14Z","timestamp":1544980514000},"page":"1439-1450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia"],"prefix":"10.1038","volume":"33","author":[{"given":"Jong-Ho","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Min","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia Moonkyung","family":"Youm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Hee","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Naka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Ju","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June-Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis (Dong Hwan)","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,16]]},"reference":[{"key":"321_CR1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med. 2003;348:994\u20131004.","journal-title":"New Engl J Med"},{"key":"321_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851.","journal-title":"J Clin Oncol"},{"key":"321_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"321_CR4","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528\u201335.","journal-title":"Lancet Haematol"},{"key":"321_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","volume":"20","author":"FX Mahon","year":"2014","unstructured":"Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20:310\u201322.","journal-title":"Clin Cancer Res"},{"key":"321_CR6","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-10-1638","volume":"16","author":"DH Kim","year":"2010","unstructured":"Kim DH, Kong JH, Byeun JY, Jung CW, Xu W, Liu X, et al. The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2010;16:5339\u201350.","journal-title":"Clin Cancer Res"},{"key":"321_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/annonc\/mdp452","volume":"21","author":"DH Kim","year":"2010","unstructured":"Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol. 2010;21:1179\u201388.","journal-title":"Ann Oncol"},{"key":"321_CR8","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15:4750\u20138.","journal-title":"Clin Cancer Res"},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-012-1142-6","volume":"96","author":"JH Kong","year":"2012","unstructured":"Kong JH, Mun YC, Kim S, Choi HS, Kim YK, Kim HJ, et al. Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. Int J Hematol. 2012;96:327\u201333.","journal-title":"Int J Hematol"},{"key":"321_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263\u20135.","journal-title":"Bioinformatics"},{"key":"321_CR11","doi-asserted-by":"publisher","first-page":"e1000529","DOI":"10.1371\/journal.pgen.1000529","volume":"5","author":"BN Howie","year":"2009","unstructured":"Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5:e1000529.","journal-title":"PLoS Genet"},{"key":"321_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/ng.2354","volume":"44","author":"B Howie","year":"2012","unstructured":"Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44:955\u20139.","journal-title":"Nat Genet"},{"key":"321_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nmeth.1785","volume":"9","author":"O Delaneau","year":"2011","unstructured":"Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods. 2011;9:179\u201381.","journal-title":"Nat Methods"},{"key":"321_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nmeth.2307","volume":"10","author":"O Delaneau","year":"2013","unstructured":"Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods. 2013;10:5\u20136.","journal-title":"Nat Methods"},{"key":"321_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nature06258","volume":"449","author":"C International HapMap","year":"2007","unstructured":"International HapMap C, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851\u201361.","journal-title":"Nature"},{"key":"321_CR16","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gkj144","volume":"34","author":"AS Hinrichs","year":"2006","unstructured":"Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, et al. The UCSC Genome Browser Database: update 2006. Nucleic Acids Res. 2006;34:D590\u20138.","journal-title":"Nucleic Acids Res"},{"key":"321_CR17","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/bioinformatics\/btq419","volume":"26","author":"RJ Pruim","year":"2010","unstructured":"Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336\u20137.","journal-title":"Bioinformatics"},{"key":"321_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"321_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra0905980","volume":"363","author":"TA Manolio","year":"2010","unstructured":"Manolio TA. Genomewide association studies and assessment of the risk of disease. New Engl J Med. 2010;363:166\u201376.","journal-title":"New Engl J Med"},{"key":"321_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1126\/science.1110359","volume":"308","author":"JL Haines","year":"2005","unstructured":"Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419\u201321.","journal-title":"Science"},{"key":"321_CR21","doi-asserted-by":"publisher","first-page":"1235587","DOI":"10.1126\/science.1235587","volume":"342","author":"E Khurana","year":"2013","unstructured":"Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, Lappalainen T, et al. Integrative annotation of variants from 1092 humans: application to cancer genomics. Science. 2013;342:1235587.","journal-title":"Science"},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1101\/gr.137323.112","volume":"22","author":"AP Boyle","year":"2012","unstructured":"Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790\u20137.","journal-title":"Genome Res"},{"key":"321_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng.3220","volume":"47","author":"X Zhang","year":"2015","unstructured":"Zhang X, Joehanes R, Chen BH, Huan T, Ying S, Munson PJ, et al. Identification of common genetic variants controlling transcript isoform variation in human whole blood. Nat Genet. 2015;47:345\u201352.","journal-title":"Nat Genet"},{"key":"321_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nature08872","volume":"464","author":"JK Pickrell","year":"2010","unstructured":"Pickrell JK, Marioni JC, Pai AA, Degner JF, Engelhardt BE, Nkadori E, et al. Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature. 2010;464:768\u201372.","journal-title":"Nature"},{"key":"321_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrg3891","volume":"16","author":"FW Albert","year":"2015","unstructured":"Albert FW, Kruglyak L. The role of regulatory variation in complex traits and disease. Nat Rev Genet. 2015;16:197\u2013212.","journal-title":"Nat Rev Genet"},{"key":"321_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2016.01.029","volume":"164","author":"X Yang","year":"2016","unstructured":"Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, et al. Widespread expansion of protein interaction capabilities by alternative splicing. Cell. 2016;164:805\u201317.","journal-title":"Cell"},{"key":"321_CR27","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3:e00149.","journal-title":"Pharmacol Res Perspect"},{"key":"321_CR28","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","volume":"23","author":"MA Larkin","year":"2007","unstructured":"Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23:2947\u20138.","journal-title":"Bioinformatics"},{"key":"321_CR29","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R. BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34\u2009+\u2009cells. Blood. 2004;103:3167\u201374.","journal-title":"Blood"},{"key":"321_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925\u201332.","journal-title":"Blood"},{"key":"321_CR31","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22:1276\u2013312.","journal-title":"Genes Dev"},{"key":"321_CR32","first-page":"44","volume":"2","author":"JB Demoulin","year":"2012","unstructured":"Demoulin JB, Montano-Almendras CP. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res. 2012;2:44\u201356.","journal-title":"Am J Blood Res"},{"key":"321_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","volume":"45","author":"E Hamilton","year":"2016","unstructured":"Hamilton E, Infante JR. Targeting CDK4\/6 in patients with cancer. Cancer Treat Rev. 2016;45:129\u201338.","journal-title":"Cancer Treat Rev"},{"key":"321_CR34","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547\u201366.","journal-title":"Nat Rev Drug Discov"},{"key":"321_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433\u20137.","journal-title":"Nature"},{"key":"321_CR36","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1194\/jlr.M025700","volume":"53","author":"M Arnedo","year":"2012","unstructured":"Arnedo M, Menao S, Puisac B, Teresa-Rodrigo ME, Gil-Rodriguez MC, Lopez-Vinas E, et al. Characterization of a novel HMG-CoA lyase enzyme with a dual location in endoplasmic reticulum and cytosol. J Lipid Res. 2012;53:2046\u201356.","journal-title":"J Lipid Res"},{"key":"321_CR37","doi-asserted-by":"publisher","first-page":"33227","DOI":"10.1074\/jbc.M112.393231","volume":"287","author":"C Montgomery","year":"2012","unstructured":"Montgomery C, Pei Z, Watkins PA, Miziorko HM. Identification and characterization of an extramitochondrial human 3-hydroxy-3-methylglutaryl-CoA lyase. J Biol Chem. 2012;287:33227\u201336.","journal-title":"J Biol Chem"},{"key":"321_CR38","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.1182\/blood-2011-01-329797","volume":"117","author":"DH Kim","year":"2011","unstructured":"Kim DH, Lee ST, Won HH, Kim S, Kim MJ, Kim HJ, et al. A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood. 2011;117:6906\u201311.","journal-title":"Blood"},{"key":"321_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125:90\u2013101.","journal-title":"Blood"},{"key":"321_CR40","doi-asserted-by":"crossref","unstructured":"Zheng Q, Cao J, Hamad N, Kim HJ, Moon JH, Sohn SK, et al. Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. J Transl Med. 2016;14:82.","DOI":"10.1186\/s12967-016-0837-5"},{"key":"321_CR41","doi-asserted-by":"crossref","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-75.","DOI":"10.1086\/519795"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0321-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:36:20Z","timestamp":1684618580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,16]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0321-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,16]]},"assertion":[{"value":"30 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}